Study at a glance
What was studied?
This review compares eight underlying studies of immune restraint and autoimmune outcomes. Autoimmunity means responses against the body’s own material. Some studies exposed human cells to active vitamin D hormone in the laboratory. Others assigned people by chance to vitamin D3 or an inactive comparison.
What was found?
Active vitamin D hormone supported some restraining functions in cultured cells. One human trial did not clearly increase the share of blood cells identified as natural regulatory T cells, which help restrain responses. Updated VITAL results left uncertainty about fewer autoimmune diagnoses. PREVANZ found no clear difference on a combined outcome of new clinical episodes or scan changes. D-Lay MS improved a combined outcome mainly involving scans, without clear improvement in clinical episodes alone or disability.
What does it mean?
Measured cell proteins, short tests of whether cells restrain other cells and autoimmune diagnoses are different outcomes. The clinical trials did not show that the laboratory mechanisms caused their results.
What are the limits?
Later VITAL follow-up watched participants after assigned supplements stopped. It was not another treatment period assigned by chance. Early neurological disease differs from prevention in healthy people. No personal dose or blood target for tolerance was established.
Read the full article below ↓Vitamin D can support some immune-regulating functions in laboratory cells. Autoimmune diseases involve responses against the body’s own material. Human trials do not show that these mechanisms reliably prevent such diseases. Updated VITAL findings, a trial measuring the share of blood cells that help restrain responses and two early multiple-sclerosis trials give different and qualified results. The detailed counterpart is Vitamin D, Immune Tolerance Mechanisms and Autoimmune Outcomes: Full Evidence Review.
What does immune tolerance mean?
Immune tolerance limits inappropriate responses, including attacks on the body’s own material. T cells help coordinate immunity. Regulatory T cells help restrain responses. Dendritic cells can also contribute. Dendritic cells display material to T cells and influence their activation. A change in a marker, a measured protein used as a clue to cell activity, does not by itself demonstrate lasting tolerance. Vitamin D and Immune Tolerance explains the wider subject.
This review assessed eight underlying studies. Laboratory experiments, blood-cell measurements and disease outcomes tested different steps. The original and updated VITAL papers came from the same trial, so they are not independent confirmations.
What did the cell studies show?
In human T-cell cultures, calcitriol, the active vitamin D hormone, supported characteristics associated with restraint under particular conditions. Other cell signals, including interleukin-2, mattered. Cells grown with calcitriol restrained other cells in a short test, but some markers later declined. This did not prove permanent self-tolerance. [1]
Another study showed that dendritic cells, which help present material to T cells, could convert precursor into active hormone in the tested cultures. Precursor means a form requiring conversion before it acts as hormone. Its availability affected the T-cell response. It did not establish a blood concentration that guarantees tolerance. Direct active-hormone exposure is different from taking vitamin D3 by mouth. [2]
Ferreira’s dendritic-cell experiments connected reduced stimulation of T cells with changes in how cells used nutrients. The cells were not simply using less energy. Garcia’s study added information about how cells made fatty acids, components of fats, and about measured cell proteins, but did not directly test T-cell suppression. Neither study demonstrated autoimmune prevention in people. [3] [4]
Did supplementation increase regulatory cells in people?
D-SIRe2 assigned sixty-two healthy adults by chance to 400 international units of vitamin D3 daily or placebo, an inactive comparison, for forty-three weeks. Vitamin D status increased, but the share of measured blood cells identified as natural regulatory T cells did not clearly rise. These cells help restrain immune responses. The seasonal increase in stimulated interferon-gamma, an immune signalling protein, was smaller with supplementation. Autoimmune disease was not measured. This result limits simple translation from cultured cells while leaving other regimens and tissue functions unresolved. [5]
What happened in VITAL?
VITAL studied older adults who were not selected for vitamin D deficiency. Its original report suggested fewer confirmed autoimmune diagnoses with vitamin D. After more diagnoses were checked, the result for the assigned-treatment period was less decisive. Its uncertainty range still allowed no difference. The combined result including later follow-up also did not establish a benefit. [6] [9]
During the additional two years, researchers watched participants after assigned study supplements stopped. They were not two more years of continuous randomized supplementation. The VITAL trial’s two reports did not show that regulatory T cells or dendritic cells caused the clinical findings.
Why do the two early neurological trials differ?
PREVANZ studied people after an initial neurological syndrome and found no clear benefit for its combined outcome of a new clinical episode or new changes on scans. It was smaller than planned and mostly involved people with adequate vitamin D status. [7]
D-Lay MS found fewer events on a combined outcome of a new clinical episode or MRI changes. MRI means magnetic resonance imaging, a scan used to examine tissue. The result was driven mainly by imaging. A new clinical episode alone and disability did not clearly improve. These participants already had early disease-related features; this was not prevention in healthy people. [8]
Different populations, schedules and follow-up may matter, but the trials did not directly compare daily with intermittent dosing. Their disagreement does not prove which feature explains the results. The high research doses are not personal treatment instructions.
What can the evidence support?
Vitamin D and Adaptive Immunity concerns adaptive immune responses, while Vitamin D and Immune Modulation concerns how responses are regulated. Vitamin D and Autoimmune Mechanisms addresses mechanisms of autoimmunity. These related questions still need different measurements.
The evidence supports regulation under particular experimental conditions and uncertainty about clinical prevention. It does not establish a personal dose, a target blood concentration for tolerance or proof that exposing cells to hormone in the laboratory explains fewer autoimmune diagnoses in people.
Primary sources
[1] Jeffery LE et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. Journal of immunology (Baltimore, Md. : 1950). 2009;183(9):5458-5467. DOI: 10.4049/jimmunol.0803217. PMID: 19843932.
[2] Jeffery LE et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. Journal of immunology (Baltimore, Md. : 1950). 2012;189(11):5155-5164. DOI: 10.4049/jimmunol.1200786. PMID: 23087405.
[3] Ferreira GB et al. Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways. Cell reports. 2015;10(5):711-725. DOI: 10.1016/j.celrep.2015.01.013. PMID: 25660022.
[4] Garcia AM et al. Tolerogenic effects of 1,25-dihydroxyvitamin D on dendritic cells involve induction of fatty acid synthesis. The Journal of steroid biochemistry and molecular biology. 2021;211:105891. DOI: 10.1016/j.jsbmb.2021.105891. PMID: 33785437.
[5] Maboshe W et al. Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial. Frontiers in immunology. 2021;12:623087. DOI: 10.3389/fimmu.2021.623087. PMID: 34262557.
[6] Hahn J et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ (Clinical research ed.). 2022;376:e066452. DOI: 10.1136/bmj-2021-066452. PMID: 35082139.
[7] Butzkueven H et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain : a journal of neurology. 2024;147(4):1206-1215. DOI: 10.1093/brain/awad409. PMID: 38085047.
[8] Thouvenot E et al. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA. 2025;333(16):1413-1422. DOI: 10.1001/jama.2025.1604. PMID: 40063041.
[9] Costenbader KH et al. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2024;76(6):973-983. DOI: 10.1002/art.42811. PMID: 38272846.
Related reading
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks.
Original paper ↗Read more →Vitamin D, Immune Tolerance Mechanisms and Autoimmune Outcomes: Full Evidence Review
T-cell and dendritic-cell mechanisms compared with autoimmune and early multiple-sclerosis trials, including null findings and uncertain clinical translation.
Read more →The Role of Vitamin D in Autoimmune Diseases
Vitamin D is a steroid hormone whose relevant immunomodulatory role has been widely described.
Original paper ↗Read more →The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto’s Thyroiditis
Although the biological implications of these data need to be further investigated, we have highlighted the relevance of studies comparing different autoimmune pathologies for the understanding of the core concepts of autoimmunity.
Original paper ↗Read more →The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase
This study investigated how 25(OH)Vitamin D status affected the effectiveness of oligo fucoidan in patients with HBV infection in the immune tolerance phase.
Original paper ↗Read more →Placental Vitamin D Signalling, Fetal Development and Immune Tolerance: Full Evidence Review
Human placental and decidual studies assess vitamin D signalling, fetal development and immune tolerance, with clinical and source-access limits.
Read more →Placental Vitamin D Signalling, Fetal Development and Immune Tolerance: Study Summary
Plain-English findings on placental vitamin D signalling: what cell studies show, what remains uncertain, and why they do not prove pregnancy benefits.
Read more →Vitamin D and Immune Tolerance
Immune tolerance is the ability of the immune system to avoid inappropriate reactions against self and harmless exposures.
Read more →Vitamin D and Autoimmune Mechanisms
Learn how vitamin D relates to autoimmune mechanisms, including immune tolerance, cytokine balance, receptor signalling, and regulatory immune pathways.
Read more →The Relationship Between Autoimmune Disorders and Multiple Sclerosis: Clinical Insights and Therapeutic Approaches
This study investigated the prevalence of AIDs among Polish patients with MS (PwMSs) and its potential effects on disease characteristics.
Original paper ↗Read more →Vitamin D, CTLA-4 and Immune Restraint: Full Study
Human T-cell experiments link active vitamin D to CTLA-4-mediated immune restraint.
Read more →Vitamin D, CTLA-4 and Immune Restraint: Study Summary
Summary of human T-cell research on vitamin D, CTLA-4 and immune restraint, explaining what the experiments show and what they cannot establish.
Read more →Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function
Therefore, in this study we have examined the effects of Th17 polarising conditions on CTLA-4 expression and function in human T cells and show that Th17 conditions can suppress the expression of CTLA-4 and its transendocytic function.
Original paper ↗Read more →Linking Mechanisms of Vitamin D Signaling with Multiple Sclerosis
Environmental triggers often work via signal transduction cascades that modulate the epigenome and transcriptome of cell types involved in the disease process.
Original paper ↗Read more →Vitamin D, the immune system, and its relationship with diseases
Vitamin D is classified as an immunomodulatory hormone that is synthesized because of skin exposure to sunlight.
Original paper ↗Read more →Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis
For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS.
Original paper ↗Read more →COVID-19 and Multiple Sclerosis: A Complex Relationship Possibly Aggravated by Low Vitamin D Levels
COVID-19 can evolve into a severe disease associated with immediate and delayed sequelae in different organs, including the central nervous system (CNS).
Original paper ↗Read more →Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients
Tolerogenic dendritic cells (tolDC) have been postulated as a potent immunoregulatory therapy for autoimmune diseases such as multiple sclerosis (MS).
Original paper ↗Read more →Disability progression in multiple sclerosis: a latent class analysis of predictors
We aimed to identify patterns of disability progression and their determinants to improve individualized risk assessment and support clinical decision-making.
Original paper ↗Read more →Does Vitamin D Supplementation Slow Brain Volume Loss in Multiple Sclerosis? A 4-Year Observational Study
However, current randomized clinical trials provide conflicting evidence about the beneficial role of vitamin D on disease progression.
Original paper ↗Read more →Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?
Disease-modifying medications, which mainly aim to suppress such aberrant immune response, have significantly improved MS treatment.
Original paper ↗Read more →Original sources
1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3
Published in Journal of immunology (Baltimore, Md. : 1950) (2009).
Publication details
[1] Jeffery LE et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. Journal of immunology (Baltimore, Md. : 1950). 2009;183(9):5458-5467. DOI: 10.4049/jimmunol.0803217. PMID: 19843932.
Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses
Published in Journal of immunology (Baltimore, Md. : 1950) (2012).
Publication details
[2] Jeffery LE et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. Journal of immunology (Baltimore, Md. : 1950). 2012;189(11):5155-5164. DOI: 10.4049/jimmunol.1200786. PMID: 23087405.
Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways
Published in Cell reports (2015).
Publication details
[3] Ferreira GB et al. Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways. Cell reports. 2015;10(5):711-725. DOI: 10.1016/j.celrep.2015.01.013. PMID: 25660022.
Tolerogenic effects of 1,25-dihydroxyvitamin D on dendritic cells involve induction of fatty acid synthesis
Published in The Journal of steroid biochemistry and molecular biology (2021).
Publication details
[4] Garcia AM et al. Tolerogenic effects of 1,25-dihydroxyvitamin D on dendritic cells involve induction of fatty acid synthesis. The Journal of steroid biochemistry and molecular biology. 2021;211:105891. DOI: 10.1016/j.jsbmb.2021.105891. PMID: 33785437.
Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial
Published in Frontiers in immunology (2021).
Publication details
[5] Maboshe W et al. Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial. Frontiers in immunology. 2021;12:623087. DOI: 10.3389/fimmu.2021.623087. PMID: 34262557.
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
Published in BMJ (Clinical research ed.) (2022).
Publication details
[6] Hahn J et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ (Clinical research ed.). 2022;376:e066452. DOI: 10.1136/bmj-2021-066452. PMID: 35082139.
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks.
Publication details
[7] Butzkueven H et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain : a journal of neurology. 2024;147(4):1206-1215. DOI: 10.1093/brain/awad409. PMID: 38085047.
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial
Published in JAMA. 2025;333(16):1413-1422. DOI: 10.1001/jama (2025).
Publication details
[8] Thouvenot E et al. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA. 2025;333(16):1413-1422. DOI: 10.1001/jama.2025.1604. PMID: 40063041.
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
Published in Arthritis & rheumatology (Hoboken, N.J.) (2024).
Publication details
[9] Costenbader KH et al. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2024;76(6):973-983. DOI: 10.1002/art.42811. PMID: 38272846.